A new Korean Research Investment for Global Health Technology (RIGHT) Fund to advance innovative neglected-disease technologies.


Journal

PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488

Informations de publication

Date de publication:
09 2020
Historique:
entrez: 4 9 2020
pubmed: 4 9 2020
medline: 28 10 2020
Statut: epublish

Résumé

In 2018, the government of the Republic of Korea (ROK), South Korean life science companies, and a group of international funders led by the Bill & Melinda Gates Foundation launched a new and innovative funding agency to support neglected-disease research and development (R&D). The new venture is known as the Research Investment for Global Health Technology (RIGHT) Fund.

Identifiants

pubmed: 32881862
doi: 10.1371/journal.pntd.0007956
pii: PNTD-D-19-01622
pmc: PMC7470318
doi:

Types de publication

Editorial

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0007956

Déclaration de conflit d'intérêts

I have read the journal's policy and the authors of this manuscript have the following competing interests: GR has an interest in the financial success of two public health impact investment funds, Global Health Investment Fund I, LLC, and Adjuvant Global Health Technology Fund, LP, where he holds investment advisory roles. Both organizations may benefit from grant funding provided by the organizations described in this publication. Equally, both organizations may be disadvantaged by grant funding provided flowing to competing technologies.

Références

Korean J Parasitol. 2006 Sep;44(3):177-85
pubmed: 16969055
Lancet Glob Health. 2013 Oct;1(4):e184-5
pubmed: 25104343
PLoS Biol. 2017 Nov 9;15(11):e2004186
pubmed: 29121043

Auteurs

Peter J Hotez (PJ)

RIGHT Fund, Seoul, Republic of Korea.
Texas Children's Hospital Center for Vaccine Development, National School of Tropical Medicine, Baylor College of Medicine, Houston, Texas, United States of America.

Kim Bush (K)

RIGHT Fund, Seoul, Republic of Korea.
Life Sciences Partnerships, Bill & Melinda Gates Foundation, Seattle, Washington, United States of America.

Andrin Oswald (A)

RIGHT Fund, Seoul, Republic of Korea.
Life Sciences Partnerships, Bill & Melinda Gates Foundation, Seattle, Washington, United States of America.

Glenn Rockman (G)

RIGHT Fund, Seoul, Republic of Korea.
Adjuvant Capital, New York, New York, United States of America.

In-Taek Lim (IT)

RIGHT Fund, Seoul, Republic of Korea.
Korean Ministry of Health and Welfare (MOHW), Sejong, Republic of Korea.

Youngmee Jee (Y)

RIGHT Fund, Seoul, Republic of Korea.
Center for Infectious Disease Research at the National Institute of Health, Korea Centers for Disease Control & Prevention (CDC), Osong, Republic of Korea.

Chang Jin Moon (CJ)

RIGHT Fund, Seoul, Republic of Korea.

Jerome H Kim (JH)

International Vaccine Institute (IVI), Seoul, Republic of Korea.

Younbeen Kim (Y)

RIGHT Fund, Seoul, Republic of Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH